BriaCell to Showcase Strong Anti-Cancer Effects of Bria-OTS+™ in Breast and Prostate Cancer Studies
Bria-OTS+ Platform Presentation: BriaCell Therapeutics will present its next generation Bria-OTS+ platform, showcasing its strong anti-cancer activity and immune system engagement at the SITC Annual Meeting on November 7, 2025.
Clinical Trials and Funding: The lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have completed GMP manufacturing and are set for clinical trials, with Bria-PROS+ receiving a $2 million NCI SBIR award to support its evaluation.
Innovative Immunotherapy: Bria-OTS+ is an advanced immunotherapy platform designed to enhance immune engagement through multiple immune-activating cytokines and co-stimulatory molecules, building on the positive results of its predecessor, Bria-OTS™.
Company Overview: BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care, with more information available on their website.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on BCTXW
No data
About the author
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
